ESMO 2021 | DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer
Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate is approved by the US FDA for patients with advanced HER2-positive metastatic breast cancer based on the results from DESTINY-Breast01 (NCT03248492). Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, presents the practice-changing results of DESTINY-Breast03 study (NCT03529110), a Phase III trial comparing the efficacy and safety of T-DXd versus trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. T-DXd demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival vs T-DM1 in this patient population with manageable toxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Cortes reports consulting/advisor: Roche , Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini.
Dr Cortes reports honoraria: Roche , Novartis , Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo.
Dr Cortes reports research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London.
Dr Cortes reports stock, patents and intellectual property: MedSIR
Dr Cortes reports travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo
